Anti-cancer effects of Panitumumab

Panitumumab (Panitumumab) specifically binds to EGFR on normal and tumor cells and competitively inhibits the binding of EGFR ligands. EGFR is a transmembrane glycoprotein and a member of the type I receptor tyrosine kinase subfamily, including EGFR, HER2, HER3 and HER4. EGFR is overexpressed in certain human cancers, including colon and rectal cancers. Non-clinical studies have shown that the binding of panitumumab to EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-related kinases, thereby inhibiting cell growth, inducing apoptosis, reducing the production of pro-inflammatory cytokines and vascular growth factors, and the internalization of EGFR. In vitro experiments and in vivo animal studies have shown that panitumumab inhibits the growth and survival of selected human tumor cell lines expressing EGFR.